Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

AACR 2026 saw thousands gathered in San Diego, California, where major progress in cancer research was revealed.

Delve into the field of PARP inhibitors, a class that has gained traction in ovarian, breast, and prostate cancers.

Discover some of the new atopic dermatitis treatments in clinical development that could overcome existing challenges in the ...

Discover eight allergy companies leading the way in 2026, developing allergy therapies that go beyond emergency management.

VCs and universities struggle with different goals and timelines, but tech transfer is helping turn academic science into ...

Phage therapy is emerging as a potential solution to antibiotic resistance and superbugs, with clinical advances in ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

First, let’s take a look at the private biotech investments in March 2026, breaking them down by value, location, funding type, and therapeutic subsector. Last month saw artificial intelligence ...

Cell and gene therapies are moving towards correcting root causes of diseases. Let's take a look at future cell and gene therapy trends.

Last week, GSK agreed to acquire Canadian biotech 35Pharma for $950 million, adding a new pulmonary hypertension program to its respiratory and cardiopulmonary pipeline. The deal is built around HS235 ...